Key result
Endothelin receptor antagonists may improve structure and function in progressive renal disorders.
Why the study?
Do endothelin receptor antagonists improve structural and functional outcomes in progressive renal disorders?
Do endothelin receptor antagonists improve structural and functional outcomes in progressive renal disorders?
Endothelin receptor antagonists may offer a therapeutic approach for progressive renal disorders associated with glomerular and tubulointerstitial damage.
Endothelin antagonists merit prospective trials in renal disease; leaves open clinical utility pending randomized confirmation.
Endothelin (ET)-1 is a potent vasoconstrictor with profibrotic and proinflammatory effects. Increasing evidence suggests that ET-1 and its cognate receptors are involved in a variety of progressive renal disorders, including diabetes, hypertension and glomerulonephritis. Several laboratory studies have demonstrated elevated expression of ET-1, which colocalizes with glomerular and tubulointerstitial injury, in addition to enhanced urinary excretion. Moreover, ET-1 expression correlates with disease severity and renal function. With the availability of ET receptor antagonists, a pathogenetic role has been further corroborated in animal models, demonstrating both structural and functional improvement. Thus, antagonizing the ET system may be useful in major renal pathologies associated with glomerular and tubulointerstitial damage.
No takes yet. Share an insight, caveat, or question.
Claus M Richter (2006) conducted a review in Chronic renal failure. Endothelin receptor antagonists was evaluated. Endothelin-1 and its receptors are involved in progressive renal disorders, and antagonizing the ET system may offer structural and functional improvements in major renal pathologies.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: